Explore

Trendline Trendline
Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success
Trendline Trendline
BrainStorm Cell Therapeutics Prepares for Phase 3 ALS Study Amid Financial Challenges

BrainStorm Cell Therapeutics Prepares for Phase 3 ALS Study Amid Financial Challenges

BrainStorm Cell Therapeutics Prepares for Phase 3 ALS Study Amid Financial Challenges
Trendline Trendline
Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments

Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments

Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments
Trendline Trendline
Atossa Therapeutics Hosts Event on (Z)-Endoxifen for ER-Positive Breast Cancer

Atossa Therapeutics Hosts Event on (Z)-Endoxifen for ER-Positive Breast Cancer

Atossa Therapeutics Hosts Event on (Z)-Endoxifen for ER-Positive Breast Cancer
Trendline Trendline
Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026
Trendline Trendline
Atossa Therapeutics to Host Event on (Z)-Endoxifen for ER-Positive Breast Cancer

Atossa Therapeutics to Host Event on (Z)-Endoxifen for ER-Positive Breast Cancer

Atossa Therapeutics to Host Event on (Z)-Endoxifen for ER-Positive Breast Cancer
Trendline Trendline
Cabaletta Bio Reports Increased Net Loss in Q1 2026 Amid Ongoing Clinical Developments

Cabaletta Bio Reports Increased Net Loss in Q1 2026 Amid Ongoing Clinical Developments

Cabaletta Bio Reports Increased Net Loss in Q1 2026 Amid Ongoing Clinical Developments
Trendline Trendline
Atossa Therapeutics to Host Event on (Z)-Endoxifen for Breast Cancer

Atossa Therapeutics to Host Event on (Z)-Endoxifen for Breast Cancer

Atossa Therapeutics to Host Event on (Z)-Endoxifen for Breast Cancer
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion

Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion

Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion
Trendline Trendline
FDA Approves BeOne's Beqalzi for Mantle Cell Lymphoma, Expanding Treatment Options

FDA Approves BeOne's Beqalzi for Mantle Cell Lymphoma, Expanding Treatment Options

FDA Approves BeOne's Beqalzi for Mantle Cell Lymphoma, Expanding Treatment Options
Trendline Trendline
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials